1 recruiting, 1 withdrawn. 1 Early Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 1 | Withdrawn 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Niraparib oral capsule: new trials by email Literature Review of Niraparib oral capsule trials Research Report on Niraparib oral capsule
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy Niraparib oral capsule, SBRT - Ovarian Cancer Recurrent | Phase 2 | Recruiting | Institute of Cancer Research, United Kingdom | 42 | 2024-06-20 | 2026-07-13 |
| Niraparib in High-grade Endometrial Cancer Trial Niraparib oral capsule - Endometrial Cancer, Serous Adenocarcinoma | Early Phase 1 | Withdrawn | Sir Mortimer B. Davis - Jewish General Hospital | 2024-05-01 | 2024-12-19 |
Cystadenocarcinoma, Serous (1) · Endometrial Neoplasms (1) · Ovarian Neoplasms (1) · Uterine Neoplasms (1)
Institute of Cancer Research, United Kingdom (1) · Sir Mortimer B. Davis - Jewish General Hospital (1)
United Kingdom (1)
Shannon Salvador, MD MSc (1) · Susana Banerjee (1) · Walter Gotlieb, MD PhD (1)